Clinical Trials Sponsored by Vir Biotechnology, Inc.

Total 295 results

Vir Biotechnology, Inc.

Recruiting

A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218

Renal Impairment

United States
Vir Biotechnology, Inc.

Recruiting

Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434

Cirrhosis | Hepatic Impairment

United States
Vir Biotechnology, Inc.

Recruiting

SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.

Hepatitis D, Chronic

New Zealand, United Kingdom, Moldova, Republic of, Romania, Bulgaria, Italy, Germany, France, Netherlands
Vir Biotechnology, Inc.

Active, not recruiting

A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection

Hepatitis B, Chronic

Hong Kong, Korea, Republic of, United Kingdom, France, Moldova, Republic of, Romania
Vir Biotechnology, Inc.

Recruiting

Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection (MARCH)

Hepatitis B, Chronic

Hong Kong, Korea, Republic of, Malaysia, New Zealand, Taiwan, United Kingdom, Romania, United States, Moldova, Republic of, Canada, Germany, Ukraine
Vir Biotechnology, Inc.

Terminated

A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A

Influenza A

United States
Vir Biotechnology, Inc.

Completed

Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection

Chronic Hepatitis B

Germany, Hong Kong, Korea, Republic of, New Zealand, Romania, Singapore, United Kingdom
Vir Biotechnology, Inc.

No longer available

Sotrovimab Expanded Access Treatment Protocol (COVID-19)

Covid19

United States
Vir Biotechnology, Inc.

Completed

Study of VIR-2482 in Healthy Volunteers

Influenza A

Australia
Vir Biotechnology, Inc.
GlaxoSmithKline

Recruiting

Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC) (COSMIC)

Covid19

United States
Vir Biotechnology, Inc.
GlaxoSmithKline

Terminated

Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.

Covid19

United States, France, Ukraine
Vir Biotechnology, Inc.
GlaxoSmithKline

Completed

VIR-7831 for the Early Treatment of COVID-19 in Outpatients (COMET-ICE)

Covid19

United States, Canada, Spain, Austria, Brazil, Peru, United Kingdom
GlaxoSmithKline
Vir Biotechnology, Inc.

Terminated

Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19 (COMET-PACE)

COVID-19

United States
Vir Biotechnology, Inc.
GlaxoSmithKline

Completed

Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19 (COMET-PEAK)

Covid19

United States, Canada, Italy, Korea, Republic of, Spain
Vir Biotechnology, Inc.
GlaxoSmithKline

Completed

A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants

Covid19

United States
Vir Biotechnology, Inc.
Alnylam Pharmaceuticals

Completed

Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B

Chronic Hepatitis B

Australia, Hong Kong, Korea, Republic of, New Zealand, Thailand
Gilead Sciences
Vir Biotechnology, Inc.

Active, not recruiting

Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)

Chronic Hepatitis B

Hong Kong, Korea, Republic of, Denmark, Australia, Thailand, Singapore, United Kingdom, New Zealand
Vir Biotechnology, Inc.
Alnylam Pharmaceuticals

Active, not recruiting

Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection

Chronic Hepatitis B

Australia, Hong Kong, Korea, Republic of, Malaysia, New Zealand, Thailand
Brii Biosciences Limited
Vir Biotechnology, Inc.

Active, not recruiting

Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients

Chronic Hepatitis B Virus Infection

Singapore, Thailand, Australia, China, Korea, Republic of
Brii Biosciences Limited
VBI Vaccines Inc.; Vir Biotechnology, Inc.

Completed

Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic HBV Infection

Hepatitis B, Chronic

Australia, China, Korea, Republic of, New Zealand, Singapore, Thailand
Brii Biosciences Limited
Alnylam Pharmaceuticals; Vir Biotechnology, Inc.

Completed

Study of VIR-2218 in Patients With Chronic Hepatitis B in Mainland China

Hepatitis B, Chronic

China
Vir Biotechnology, Inc.
Bill and Melinda Gates Foundation

Completed

VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers

HIV I Infection

United States
Fred Hutchinson Cancer Center
National Marrow Donor Program; Vir Biotechnology, Inc.

Terminated

Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 Infection

United States
AVIR Green Hills Biotechnology AG

Completed

Study of Single Dose GHB16L2 Trivalent Influenza Vaccine in Healthy Adults

Influenza, Human

Austria
AVIR Green Hills Biotechnology AG

Completed

Dose Finding Study of Single Dose GHB11L1 in Healthy Adults (GHB-CS07)

Influenza, Human

Austria
AVIR Green Hills Biotechnology AG

Completed

Randomized, Double-blind, Placebo-controlled, Phase I Dose-escalation Study of Single Dose GHB01L1 in Healthy Volunteers (GHBCS-01)

Seasonal Human Influenza

Austria
AVIR Green Hills Biotechnology AG

Completed

Two Doses of GHB04L1 for Pandemic Influenza Prophylaxis in Healthy Adults

Influenza, Avian

Russian Federation
Puma Biotechnology, Inc.

Recruiting

A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer (ALISCA-Lung1)

Small Cell Lung Cancer

United States
TWi Biotechnology, Inc.

Recruiting

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

Generalized Epidermolysis Bullosa Simplex

United States, Taiwan, Australia, Philippines
BRIM Biotechnology Inc.

Not yet recruiting

Assessment of the Safety and Efficacy of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis

Neurotrophic Keratitis
Accutar Biotechnology Inc

Recruiting

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

Breast Cancer

United States
HuniLife Biotechnology, Inc.

Recruiting

A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HuL001

Idiopathic Pulmonary Fibrosis

Taiwan
Accutar Biotechnology Inc

Terminated

A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

Metastatic Castration Resistant Prostate Cancer

United States
Accutar Biotechnology Inc

Terminated

A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Breast Cancer

China
TWi Biotechnology, Inc.

Completed

A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout

Gout

Taiwan
TWi Biotechnology, Inc.

Completed

Prophylactic Treatment of Skin Rash Associated With EGFR Inhibitor Therapy

EGFR Inhibitor-Induced Skin Rash

Taiwan
TWi Biotechnology, Inc.

Completed

Tofacitinib Citrate Topical Gel 3.2% FDA BA Bridging Study

Healthy Subjects

Canada
Puma Biotechnology, Inc.

Completed

Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer (ExteNET)

Breast Cancer

United States, Spain, Korea, Republic of, China, United Kingdom, Canada, France, Australia, Denmark, Switzerland, Japan, Malaysia, Italy, Singapore, Taiwan, Belgium, Croatia, Czechia, Romania, Germany, Bahamas, Brazil, Bulgaria, Colombia and more
Unity Biotechnology, Inc.

Terminated

Long-Term Follow-Up Study of Patients With Osteoarthritis of the Knee Treated With UBX0101 or Placebo

Knee Osteoarthritis

United States
TWi Biotechnology, Inc.

Completed

A Double-blind, Intra-individual Comparison, POC Trial of AC-203 in EB Patients

Inherited Epidermolysis Bullosa

Taiwan
Puma Biotechnology, Inc.

Completed

A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor

Advanced Malignant Solid Tumors

Japan
Puma Biotechnology, Inc.

Completed

Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer

Breast Cancer | Advanced Breast Cancer

Korea, Republic of, Taiwan, Hong Kong, United States, Japan, Croatia, United Kingdom, Hungary, Australia, Canada, Serbia, Singapore, South Africa, Poland, Spain, Russian Federation, Romania, Austria, Belgium, Bulgaria, Czechia, Fr... and more
Puma Biotechnology, Inc.

Completed

A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer

Advanced Breast Cancer

United States, Switzerland, China, France
Puma Biotechnology, Inc.

Completed

Study Evaluating HKI-272 Administered to Healthy Subjects

Healthy

United States
Cougar Biotechnology, Inc.

Completed

A Safety and Efficacy Study of Abiraterone Acetate in Participants With Prostate Cancer Who Have Failed Hormone Therapy

Prostatic Neoplasms

United Kingdom
Cougar Biotechnology, Inc.

Completed

A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate Cancer

Prostate Neoplasms

United Kingdom, United States
Puma Biotechnology, Inc.

Completed

Study Evaluating The PK And Safety Of Neratinib In Healthy Subjects And Subjects With Chronic Liver Disease

Hepatic Insufficiency

Russian Federation
Hopstem Biotechnology Inc.

Recruiting

A Safety and Tolerability Study of Human Forebrain Neural Progenitor Cells Injection (hNPC01) in Subjects With Chronic Ischemic Stroke

Chronic Ischemic Stroke

China
Accutar Biotechnology Inc

Recruiting

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

Relapsed/Refractory B-cell Malignancies

United States
BRIM Biotechnology Inc.

Recruiting

Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Dry Eye Subjects.

Dry Eye Disease

United States

Clinical Trials Sponsored by Vir Biotechnology, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations